Press releases

Data was presented at SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago

Results from TAXUS IV and V randomized clinical trials favor DES compared to bare-metal stents

At two years, Company's TAXUS® and PROMUS™ Stents demonstrate positive and similar outcomes

Sale is the latest example of Company's commitment to realigning its cost structure; overall goal is to strengthen Boston Scientific for the future

Two-year outcomes confirm the favorable results seen in previous clinical trials

One-year pooled ARRIVE data showed similarly low rates of stent-related cardiac death, myocardial infarction, stent thrombosis, and major cardiac events across the two patient subsets

Presentations to include clinical data for the TAXUS® paclitaxel-eluting coronary stent in a variety of high-risk patient populations

A live webcast and replay of the March 18 session will be available. Learn how to tune in

ACUITY® Spiral lead offers flexibility for placement in small, medium and large veins

Forty implants of COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN™ implantable cardioverter defibrillator (ICD) performed in 14 hospitals in six countries

Jay J. Schnitzer, M.D., Ph.D. to join Company's Clinical Sciences organization effective March 24

Approvals include CONFIENT™ ICD, LIVIAN™ CRT-D and upgraded LATITUDE® Patient Management System

Completes Company's previously announced plans to divest five non-strategic businesses

Company plans to seek to overturn patent infringement lawsuit verdict in post-trial motions

PROENCY will provide real-world clinical data on the PROMUS™ Stent

"The turn that began last quarter continued this quarter, with strong adjusted earnings and record sales," said Jim Tobin, President and Chief Executive Officer

'Close the Gap' brings together advocates from cardiologists to coaches

A live webcast and replay of the February 6 session will be available.

NEJM article is entitled "A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications"

A live webcast and replay of the February 5 conference call will be available

CE Mark approvals are for COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN™ implantable cardioverter defibrillator (ICD)

Ruling finds the NIR® stent, formerly sold by Company, infringed one claim of a patent owned by Johnson & Johnson

Divestitures are part of ongoing efforts to simplify operating model and restore profitable growth

Company retains ownership of Pain Management business

A live webcast and replay of the January 9 session will be available

LIVIAN™ CRT-D is specifically designed to monitor heartbeats in heart failure patients and deliver small electrical impulses that may improve the heart's pumping ability

TAXUS Liberte has more CE Mark-approved indications than any other drug-eluting stent

In addition to the two sales announced today, Boston Scientific has also recently announced agreements to sell its Cardiac Surgery, Vascular Surgery and Auditory businesses

The two stent systems are identical products; would be covered by the same FDA approval

A live webcast and replay of the December 5 session will be available

A live webcast and replay of the November 28 session will be available

Settles claims associated with product communications issued by Guidant Corporation in 2005 and 2006; Company acquired Guidant last year

Integration links LATITUDE® Patient Management system to GE's Electronic Medical Record (EMR) system

Getinge Group, a global provider of healthcare equipment and systems, to buy the two businesses for cash price of $750 million

Company believes the finding of patent infringement is in error and will request the judge to overturn it

Dr. Keith Dawkins and Dr. Takahiro Uchida to join the Company

Studies evaluated the effectiveness of stenting with embolic protection for patients at high risk for carotid endarterectomy (CEA), the surgical treatment for carotid artery disease

TAXUS IV study demonstrates long-term safety and efficacy of TAXUS drug- eluting stent compared to bare-metal stent

TAXUS ATLAS studies also reinforce deliverability of TAXUS® Liberte® drug-eluting stent in long lesions and small vessels

One-year results from the SPIRIT III trial included an updated analysis of 1,002 patients with coronary artery disease

Data showed continued low incidences of adverse events and repeat revascularization through two years in complex patients

"The quarter represented a turn for us, with a number of positive developments," said Jim Tobin, President and Chief Executive Officer

Approximately 2,300 positions to be eliminated worldwide

Schedule of Company events for the Cardiovascular Research Foundation's (CRF) 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium

CE Mark for CONFIENT™ implantable cardioverter defibrillator (ICD) represents first Boston Scientific-branded cardiac rhythm management device to treat sudden cardiac death

A live webcast and replay of the October 19 conference call will be available

Data reflects the experience from the first 15,000 patients monitored wirelessly on the LATITUDE® Patient Management System

With the election of Mr. Elliott, the Boston Scientific Board increases to 15 members

Analysis of TAXUS II, IV, V and VI trials found paclitaxel-eluting stents had similar clinical outcomes in women and men, despite women’s higher risk profile

TAXUS® Stent shows no additional very late stent thrombosis

OLYMPIA launch phase results show positive outcomes in diabetic patients

Three Boston Scientific subsidiaries will pay a total of $16.75 million and admit no liability

Company plans to announce five-year results from the TAXUS II clinical trial

A live webcast and replay of the September 10 conference session will be available

Amendment to provide the Company additional financial flexibility as it implements initiatives designed to increase shareholder value

Transaction would advance company's plan to divest non-strategic assets and strengthen operating and financial performance

BSC to assume sole control of Pain Management business and emerging indications program, Advanced Bionics principals to purchase Auditory business and drug pump program

Endosurgery group to remain wholly owned by Boston Scientific

Business produces a range of products used to manage fluid and measure pressure during angiography and angioplasty procedures

"We made progress in a number of key areas during the quarter," said Jim Tobin, President and Chief Executive Officer

TAXUS PERSEUS clinical program to evaluate platinum enhanced drug-eluting stent

Successful implantation marks the beginning of the TAXUS PETAL I First Human Use (FHU) Trial

Claims associated with a series of product communications issued by Guidant Corporation in 2005 and 2006; Company acquired Guidant Corporation last year

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2007...

Hardware and software innovations offer new benefits to physicians and patients

Acquisition to bring innovative sensor and wireless communication technology, complementing Company's Cardiac Rhythm Management product line

Deal follows successful four-year exclusive distribution of Prolieve® Thermodilatation System

A live webcast and replay of the June 13 conference session will be available

Article in April 24 edition of JACC highlights shorter procedure time, lower bailout rate

Study seeks to confirm the safety and efficacy of systems in routine clinical practice

Longest drug-eluting stent approved for the management of patients with clinically challenging coronary artery disease

SPIRIT FIRST follow-up analysis shows no stent thrombosis or MACE after one year

Study highlights importance of antiplatelet therapy compliance

Trial results report no new stent thrombosis after two years in high-risk patient population

Group supports call for limiting greenhouse gas emissions

Company anticipates broad range of clinical results on endoscopic technologies

Single-operator system allows unprecedented visual access to bile duct

Company to release broad range of clinical data on leading drug-eluting stent portfolio

More than 23,000 patients now enrolled in TAXUS OLYMPIA registry

New data provide support for minimally invasive treatment of atrial fibrillation (AF)

Data represents the industry's largest experience with wireless remote monitoring of implantable cardiac devices for one year

Reimbursement granted by National Health Insurance System

RENAISSANCE trial demonstrates durable results for Company's Express® SD Renal Stent in treating hypertensive patients with severe renal artery stenosis

Sam Leno will join the Company as Chief Financial Officer (CFO) and Executive Vice President of Finance and Information Systems

SYNTAX is the first trial to compare the results of drug-eluting stents with those of cardiac surgery in the most complex patient subsets

A live webcast and replay of the May 2 conference session will be available

"I am pleased we came in at the upper end of our ranges for sales and EPS for the quarter," said Jim Tobin, President and Chief Executive Officer

Product provides enhanced control for accessing desired vessel location

A live webcast and replay of the April 23 conference call will be available.

Company has resolved deficiencies in the warning letter issued by the U.S. Food and Drug Administration (FDA) to the Guidant Corporation

Company plans to launch the product after reimbursement approval is granted

Trial is designed to identify and investigate clinically relevant endpoints for evaluating the efficacy and durability of endovascular treatment of brain aneurysms

BTK CHILL study demonstrates high rate of limb protection at one year

TAXUS® Express2™ paclitaxel-eluting coronary stent system met its primary endpoint in the treatment of in-stent restenosis

Two-year review of TAXUS Stent safety data presented at ACC

Results reaffirm strength of Boston Scientific's dual drug-eluting stent program

Compliance program is the first of its kind in the medical device industry; is expected to launch in the United States later this year

Smallest Dual Chamber System offered in Japan provides enhanced therapies to patients at risk of sudden cardiac death

Company to host analyst meeting and symposium on drug-eluting stents

A live webcast and replay of the March 19 conference session will be available